Li-Fraumeni syndrome

Common Name(s)

Li-Fraumeni syndrome

Li Fraumeni syndrome is genetic condition that increases the chances of a person developing certain cancers over a lifetime. Some of the types of cancer seen in Li Fraumeni syndrome are soft tissue sarcomas, breast cancer, and osteosarcomas (cancer of bone cells). Most of the cancers associated with Li Fraumeni syndrome appear in late childhood and early teenage years. Li Fraumeni syndrome is caused by changes (mutations) in either the CHEK2 gene or TP53 gene. These genes are known as tumor suppressor genes, which are genes that help protect the body from cancer by making sure cells divide in a controlled way. When tumor suppressor genes are not working properly, cell division and growth is not controlled, leading to the cancers seen in Li Fraumeni syndrome.

Li Fraumeni syndrome is inherited in an autosomal dominant manner. People have two copies of most genes in their body, including CHEK2 and TP53. People with Li Fraumeni syndrome are born with a mutation in only one of the two CHEK2 or TP53 gene copies they have. This means they have only one copy of the gene that works in all of their cells. If at some point in their life the other copy of the gene becomes mutated in a cell, which can happen randomly, that person will no longer have a working copy of the gene. This occurrence is what leads to the start of cancer in whatever tissue the cell is located in.

Li Fraumeni syndrome is suspected in a person who has one of the related cancers at a young age, usually before the age of 50 years, as well as a family history of related cancers. The diagnosis is confirmed with genetic testing. Aggressive screening, including imaging and blood studies, are recommended to identify cancer at an early stage in people with Li Fraumeni syndrome. If your child has been diagnosed with Li Fraumeni syndrome, talk with their doctor to discuss treatment and screening recommendations. Support groups can help connect you with other affected families.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Li-Fraumeni syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Li-Fraumeni syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Li-Fraumeni syndrome" returned 88 free, full-text research articles on human participants. First 3 results:

The psychosocial effects of the Li-Fraumeni Education and Early Detection (LEAD) program on individuals with Li-Fraumeni syndrome.
 

Author(s): Jessica Ross, Jasmina Bojadzieva, Susan Peterson, Sarah Jane Noblin, Rebecca Yzquierdo, Martha Askins, Louise Strong

Journal: Genet. Med.. 2017 Sep;19(9):1064-1070.

 

In the past 5 years, new screening protocols have been developed that provide improved cancer screening options for individuals with Li-Fraumeni syndrome (LFS). Very little has been published on the psychosocial impact of these screening protocols. The goals of this study were to ...

Last Updated: 31 Dec 1969

Go To URL
Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
 

Author(s): Jeffrey S Buzby, Shirley A Williams, Lana Schaffer, Steven R Head, Diane J Nugent

Journal: Cancer Genet. 2017 Feb;211():9-17.

 

Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder where an oncogenic TP53 germline mutation is passed from parent to child. Tumor protein p53 is a key tumor suppressor regulating cell cycle arrest in response to DNA damage. Paradoxically, some mutant TP53 carriers remain ...

Last Updated: 31 Dec 1969

Go To URL
Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy.
 

Author(s): Priscila Giavedoni, Marnie Ririe, Cristina Carrera, Susana Puig, Josep Malvehy

Journal: Acta Derm. Venereol.. 2017 Jun;97(6):720-723.

 

Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder caused by a mutation in the p53 gene. Melanoma is considered to be a rare, controversial component of LFS. The aim of this study is to describe the utility of systematic screening for melanoma in patients with LFS and ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Li-Fraumeni syndrome" returned 8 free, full-text review articles on human participants. First 3 results:

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
 

Author(s): Rishi Agarwal, Sarah Liebe, Michelle L Turski, Smruti J Vidwans, Filip Janku, Ignacio Garrido-Laguna, Javier Munoz, Richard Schwab, Jordi Rodon, Razelle Kurzrock, Vivek Subbiah,

Journal: Discov Med. 2014 Dec;18(101):331-9.

 

Cancer genetics has rapidly evolved in the last two decades. Understanding and exploring the several genetic pathways in the cancer cell is the foundation of targeted therapy. Several genomic aberrations have been identified and their role in carcinogenesis is being explored. In contrast ...

Last Updated: 31 Dec 1969

Go To URL
EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.
 

Author(s): Charles Ricordel, Marie Labalette-Tiercin, Alexandra Lespagnol, Mallorie Kerjouan, Catherine Dugast, Jean Mosser, Benoit Desrues, Hervé Léna

Journal: Lung Cancer. 2015 Jan;87(1):80-4.

 

We report two cases of non-smoker patients diagnosed with EGFR-mutated lung adenocarcinoma and bearing germinal TP53 gene mutation, also known as Li-Fraumeni syndrome (LFS). We describe for the first time an EGFR-TKI resistance mutation in this population. Finally, we provide an analysis ...

Last Updated: 31 Dec 1969

Go To URL
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.
 

Author(s): April D Sorrell, Carin R Espenschied, Julie O Culver, Jeffrey N Weitzel

Journal: Mol Diagn Ther. 2013 Feb;17(1):31-47.

 

Prevalent as an acquired abnormality in cancer, the role of tumor protein p53 (TP53) as a germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is often dramatic and affects the full life course, with a propensity to develop rare tumors in childhood ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
 

Status: Recruiting

Condition Summary: Li-Fraumeni Syndrome

 

Last Updated: 27 Mar 2018

Go to URL
Clinical and Genetic Studies of Li-Fraumeni Syndrome
 

Status: Recruiting

Condition Summary: Li-Fraumeni Syndrome; Neoplasms; Tp53 Mutations

 

Last Updated: 18 May 2018

Go to URL